Bendamustine
 | |
| Clinical data | |
|---|---|
| Trade names | Treanda |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a608034 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous infusion |
| ATC code | L01AA09 (WHO) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | NA (intravenous only) |
| Protein binding | 94–96% |
| Metabolism | Hydrolyzed to inactive metabolites. Two minor metabolites (M3 and M4) formed by CYP1A2 |
| Biological half-life | 40 min (bendamustine), 3 h (M3), 30 min (M4) |
| Excretion | ~50% urinary, ~25% fecal [1] |
| Identifiers | |
| |
| CAS Number |
16506-27-7  |
| PubChem (CID) | 65628 |
| IUPHAR/BPS | 7478 |
| ChemSpider |
59069 |
| UNII |
9266D9P3PQ |
| ChEMBL |
CHEMBL487253 |
| Chemical and physical data | |
| Formula | C16H21Cl2N3O2 |
| Molar mass | 358.262 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
Bendamustine (INN, trade names Treakisym, Ribomustin, Levact and Treanda; also known as SDX-105) is a nitrogen mustard used in the treatment of chronic lymphocytic leukemia[2] and lymphomas. It belongs to the family of drugs called alkylating agents. It is also being studied for the treatment of sarcoma.[3] It is also being investigated in phase II trials for the non-cancer treatment of AL amyloidosis.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.[4]
Medical uses
Bendamustine has been used both as sole therapy and in combination with other agents including etoposide, fludarabine, mitoxantrone, methotrexate, prednisone, rituximab, vincristine and 90Y-ibritumomab tiuxetan.
Lymphomas
One combination for stage III/IV relapsed or refractory indolent lymphomas and mantle cell lymphoma (MCL), with or without prior rituximab-containing chemoimmunotherapy treatment, is bendamustine with mitoxantrone and rituximab.[5] In Germany in 2012 it has become the first line treatment of choice for indolent lymphoma.[6] after Trial results released in June 2012 showed that it more than doubled disease progression-free survival when given along with rituximab. The combination also left patients with fewer side effects than the older R-CHOP treatment.[7]
Adverse effects
Common adverse reactions are typical for the class of nitrogen mustards, and include nausea, fatigue, vomiting, diarrhea, fever, constipation, loss of appetite, cough, headache, unintentional weight loss, difficulty breathing, rashes, and stomatitis, as well as immunosuppression, anemia, and low platelet counts. Notably, this drug has a low incidence of hair loss (alopecia) unlike most other chemotherapy drugs.[8]
Warning
FDA Safety Alert – Bendamustine (TreandaR) Solution NOT Compatible with Closed System Transfer Devices (CSTD) Situation:
- FDA issued a warning on March 11, 2015 not to use bendamustine solution with CSTDs, adapters and syringes which contain either polycarbonate or acrylonitrile-butadiene-styrene (ABS) due to the incompatibility with N,N-dimethylacetamide (DMA).
Background:
- PhaSealR & SpirosR CSTDs contain either polycarbonate or ABS can dissolve when coming into contact with bendamustine (which contains DMA).
Assessment:
- This can lead to device failure, possible product contamination, and potential serious adverse health consequences, including skin reactions in health care professionals preparing and administering this product and the risk of small blood vessel blockage in patients.
Recommendations:
- Immediately, stop using all PhaSealR &/or SpirosR products including adapters when preparing & administering bendamustine.
- Only use polypropylene syringes with bendamustine. These syringes are translucent in appearance.
- Continue to use all universal PPE & safety precautions for hazardous drugs when preparing & administering bendamustine.
Pharmacology
Bendamustine is a white, water-soluble microcrystalline powder with amphoteric properties. It acts as an alkylating agent causing intra-strand and inter-strand cross-links between DNA bases.
After intravenous infusion it is extensively metabolised in the liver by cytochrome p450. More than 95% of the drug is bound to protein - primarily albumin. Only free bendamustine is active. Elimination is biphasic with a half-life of 6–10 minutes and a terminal half-life of approximately 30 minutes. It is eliminated primarily through the kidneys.
History
Bendamustine was first synthesized in 1963 by Ozegowski and Krebs in East Germany (the former German Democratic Republic). Until 1990 it was available only in East Germany. East German investigators found that it was useful for treating chronic lymphocytic leukemia, Hodgkin’s disease, non-Hodgkin’s lymphoma, multiple myeloma and lung cancer.
Bendamustine received its first marketing approval in Germany, where it is marketed under the tradename Ribomustin, by Astellas Pharma GmbH's licensee, Mundipharma International Corporation Limited. It is indicated as a single-agent or in combination with other anti-cancer agents for indolent non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia. SymBio Pharmaceuticals Ltd. holds exclusive rights to develop and market bendamustine HCl in Japan and selected Asia Pacific Rim countries.
In March 2008, Cephalon received approval from the United States Food and Drug Administration to market bendamustine in the US, where it is sold under the tradename Treanda, for treatment of chronic lymphocytic leukemia.[9]
In October 2008, the FDA granted further approval to market Treanda for the treatment of indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.[10]
References
- ↑ "Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy". Drugs R D. March 2013. doi:10.1007/s40268-012-0001-5. Retrieved 20 June 2015.
- ↑ Kath R, Blumenstengel K, Fricke HJ, Höffken K (January 2001). "Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia". J. Cancer Res. Clin. Oncol. 127 (1): 48–54. doi:10.1007/s004320000180. PMID 11206271.
- ↑ Bagchi S (August 2007). "Bendamustine for advanced sarcoma". Lancet Oncol. 8 (8): 674. doi:10.1016/S1470-2045(07)70225-5. PMID 17726779.
- ↑ "www.who.int" (PDF).
- ↑ Weide R, Hess G, Köppler H, et al. (2007). "High anti–lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A muticenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)". Leuk. Lymphoma. 48 (7): 1299–1306. doi:10.1080/10428190701361828. PMID 17613757.
- ↑ New Combo Replaces CHOP for Lymphoma. Dec 2012
- ↑ "'Rediscovered' Lymphoma Drug Helps Double Survival: Study". June 3, 2012.
- ↑ Tageja, Nishant; Nagi, Jasdeepa; "Bendamustine: something old, something new"; Cancer Chemotherapy and Pharmacology, 2010 Aug;66(3):413-23. doi: 10.1007/s00280-010-1317-x.
- ↑ "Cephalon press release - Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia". Retrieved 2008-03-23.
- ↑ "Cephalon press release -Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma". Retrieved 2008-11-03.
External links
- Manufacturer's official website intended for US patients